Earnings Feed
Start Free
CytomX Therapeutics, Inc.·4

Aug 2, 8:55 PM ET

RAY DEBANJAN 4

4 · CytomX Therapeutics, Inc. · Filed Aug 2, 2018

Insider Transaction Report

Form 4
Period: 2018-08-01
CytomX Therapeutics, Inc.CTMX
RAY DEBANJAN
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-08-01+290→ 19,220 total
    Exercise: $1.45Exp: 2024-02-27→ Common Stock (290 underlying)
  • Exercise/Conversion

    Common Stock

    2018-08-01$1.26/sh+2,710$3,414→ 8,638 total
  • Sale

    Common Stock

    2018-08-01$26.05/sh−3,000$78,150→ 5,928 total
  • Exercise/Conversion

    Common Stock

    2018-08-01$1.45/sh+290$420→ 8,928 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-08-01+2,710→ 0 total
    Exercise: $1.26Exp: 2023-12-10→ Common Stock (2,710 underlying)
Footnotes (2)
  • [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  • [F2]100% of the shares subject to the option are fully vested and exercisable.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4